I t has been a little over 20 years since targeted gene disruption in the mouse was reported. This Perspectives article examines how we got to where we are and paints in broad strokes what we have and have not learned.
Homologous recombination was well known in the latter half of the 20th century, 1,2 but its use in the directed mutation, disruption, and alteration of the mammalian genome was hampered by the vanishingly small frequency with which it occurred. 3 However, with powerful selection techniques, these infrequent events could be detected, and in 1987 to 1988 the Smithies and Capecchi laboratories published data documenting general strategies for targeted disruption in mouse embryo-derived stem cells. 4 -6 As targeted gene disruption of the mouse genome became established, transcription factors that impacted organ development were first, obvious targets, and because mouse embryo viability is dependent on a functional heart beginning at around day 10.5 to 11 of development, the essential role(s) these factors played in cardiac development began to become apparent. 7 Scientific advances often come about because of a fortuitous mix of technology, people, and circumstance, and such was the case for a first, seminal study in which a gene known to be vital in controlling cardiac contractility was targeted for deletion. Thomas Doetschman, the first author on the paper from the Smithies' laboratory, was recruited to the University of Cincinnati, where Evangelia Kranias was working on the small protein, phospholamban. Kranias initiated a minisabbatical with Doetschman, taking on the project to "knockout" the phospholamban gene. The paper, which was published in Circulation Research in 1994, 8 not only helped to define the role phospholamban played in normal cardiac function but also brought home to the cardiovascular community the powerful approach represented by loss-of-function in the whole animal. In a single experiment, the researcher could now marry both an ultimate reductionist approach (ablating a single gene) and whole-organ and animal physiology.
Of course, systemic gene ablation was and remains a blunt instrument. A gene's product is more often than not expressed in multiple cell types, and systemic ablation has the potential of impacting multiple organ systems, which confounds interpreta-tion of the gene's specific function(s) in the heart. The more precise the tool, the easier it is to control the experiment and interpret the outcome. The cardiovascular community relatively quickly adopted more specific approaches to genetic modification, such as using multiple steps of recombination to produce site-specific gene modifications rather than total ablation or creating cell-type-specific genetic modifications/ablations with specific promoters to drive restricted expression of Cre recombinase. 9 Combinations of these approaches resulted in an inducible system that could drive Cre expression in cardiomyocytes at specific developmental times or even in the adult, which allowed the effects of the genetic modification to be explored free of confounding developmental anomalies. 10 What have we learned in the past 20 years? Although the pace of data acquisition and subsequent definition of multiple signaling pathways, gene function, and normal and pathogenic mechanisms has been exhilarating, we cannot help but be humbled by the relatively tiny impact of these data on human health in general and cardiovascular disease specifically. Our "wet bench" advances have not, with rare exceptions, 11 been translated to the bedside. Although this failure is due at least in part to our inability to effectively apply what we have learned to drug development, it also reflects remaining, serious deficits in understanding the mechanisms that drive cell and organ function.
Despite the efforts of numerous individuals and political and scientific organizations such as the European Union's Conditional Mouse Mutagenesis Programme, The National Institutes of Health, the Texas Institute for Genomic Medicine, and the North American Conditional Mouse Mutagenesis Program, gene ablation coverage of the mouse genome is only about 65% complete, as detailed on the International Knockout Mouse Consortium's Web page (http://www. knockoutmouse.org/). Compounding the inherent limitations of this deficit, the mutations placed in the consortium's repository are the result of different targeting strategies, which has the potential to lead to dramatically different outcomes, even if the same gene has been targeted. In fact, even if the same technology is used, "knockouts" from different laboratories can show different phenotypes. This was first documented rigorously in a series of null alleles created in the basic helix-loop-helix transcription factor, MRF4, by the Arnold, Olson, and Wold laboratories. Although classic gene targeting technology was used in all 3 laboratories, the targeting strategies differed slightly, with the end result of the "null" alleles creating 3 distinct phenotypes that ranged from complete lethality to unaffected viability. 12, 13 In this particular case, the cis-acting effects of the different alleles created on an adjacent gene locus, myf5, were responsible. But this result is very probably scalable to many other null alleles that have been created. Very few data have been collected that take into account these types of interac-tions, and the phenotypes that result from null alleles are invariably analyzed from the narrow viewpoint that a single gene's function has been ablated, with neighboring genes either ignored or being subjected to only cursory examination. Considering the little that we do know, it would not be at all surprising if the phenotypes already defined are also the result of modifications in neighboring gene activity.
We still don't know how to create gene-targeted animals in a time-and cost-efficient manner. Although the consortia referred to above will mitigate this issue to some extent in the future, many investigators will want or need more precisely targeted tools, such that the gene can be ablated or modified in a particular tissue at a specific developmental stage. The issues of time and cost become even more limiting when a site-directed mutation is needed in a mouse model of human cardiovascular disease, because the process is even more expensive and more laborious, with mouse construction often taking nearly 2 years and costing $20 000 to $40 000. These issues have certainly had a significant impact on progress over the last 20 years and promise, in the current funding climate, to become even more important, particularly because review panels invariably require that the investigator "make the mouse" before awarding a fundable score to the application. These practical concerns, as well as the mindset of the review panels, even when experienced investigators with a track record in successful mouse production propose a new model, has and undoubtedly will continue to hamper progress in the next decade. Pity the poor beginning investigator whose experiments depend on a mouse that he or she is proposing to make! Although new technologies such as the zinc-fingered nucleases show great promise, 14 -16 their practical application in the mouse remains tantalizingly close but out of reach for the general laboratory.
We still know discouragingly little about the general interactome or even how to study it. The interactome remains amorphous even in definition but represents the sum total of the cells' components and their interactions. Although it can be restricted to isolated systems such as metabolic pathways, chromatin regions, and protein-protein interactions, clearly we lack the tools to study it (them) in a coherent way, particularly in terms of reactivity to directed genetic modification. The various phenotypes that result from the creation of 3 "null alleles" merely represent a specialized case of the black box that the interactome can present in terms of really understanding the consequences of a single, directed mutation in the genome and what really is responsible for the observed phenotype. Of course, we can clearly define the primary genetic cause responsible for the deficit(s). But the pathogenic processes that result from either the gene's ablation or mutation are often obscured, either by systemic effects, the creation of an undefined hypoallele for the gene that was (presumably) ablated, or subtle developmental deficits that manifest themselves later in the animal's life. A rigorous approach to the interactions and networks that truly underlie the phenotype brought about as the result of either a gene's ablation or modification currently escapes us. Rather, we are largely restricted to looking at isolated parts, even in the context of whole-animal physiology.
The era of gene targeting's first iteration is drawing to a close. Its next manifestation will be faster, cheaper, and more accessible. But to match those advances, our abilities to analyze the phenotypes at both the reductionist and holistic levels will require novel training programs and collaborations between the cardiovascular, engineering, and bioinformatics communities. Although some institutions have taken the first steps toward coherent development of these integrated communities, productive collaborations and integrated strategic visions remain the exception rather than the norm. This will need to change for the true potential of both the technology and the data to be realized.
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